Comparison of the effects of aminoguanidine and L-carnitine treatments on somatosensorial evoked potentials in alloxan-diabetic rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 354, Issue 4, 1996, Pages 526-531

  Yildiz, Oǧuzhan ^a   Özata, Metin ^a   Özkardeş, Abdullah ^a   Deniz, Gönen ^a   Yildirimkaya, Metin ^a   Çorakçi, Ahmet ^a   Yardim, Muzaffer ^a   Gündoǧan, Mehmet Ali ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Alloxan; Aminoguanidine; Diabetic neuropathy; L carnitine; Rat; Somatosensorial evoked potentials

Indexed keywords

AMINOGUANIDINE; CARNITINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALLOXAN DIABETES MELLITUS; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; EVOKED RESPONSE; GLUCOSE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029794780     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00168446     Document Type: Article

References (51)

1. Allison T, Huma AL (1981) A comparative analysis of short-latency somatosensory evoked potentials in man, monkey, cat and rat. Exp Ncurol 72:592-611
2. Baynes JW (1991) Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-412
3. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW. Gispen WH (1994) Cerebral function in diabetes. Diabetologia 37:643-650
4. Bravenboer B, Kappelle AC, Hamers FTP, van Buren T, Erkelens DW, Gispen WH (1992) Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 35:813-817
5. Brooks DE, McIntosh JEA (1975) Turnover of earnitine by rat tissues. Biochem J 148:439-445
6. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632
7. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Eng J Med 318:1315-1321
8. Cameron NE, Leonard MB, Ross IS, Whiting H (1986) The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia 29:168-174
9. Cameron NE, Cotter MA, Maxfield EK (1993) Antioxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 36: 299-304
10. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK (1994) Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneural blood flow and oxygen tension in non-diabetic and streptozotoein-diabetic rats. Diabetologia 37: 449-459
11. Conti M, Morand PC, Levillain P, Lemonnier A (1991) Improved flourometric determination of malonaldehyde. Clin Chem 37:1273-1275
12. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JI, Sweetland MA, Lanchester JR, Williamson JR, McDaniel MI (1992) Aminoguanidine. a novel inhibitor of nitric oxide formation. prevents diabetic vascular dysfunction. Diabetes 41: 552-556
13. Dey J, Misra A, Desai NG, Mohapatra AK, Padma MV (1995): Cerebral function in relatively young subset of NIDDM patients. Diabetologia 38:251
14. Di Giulio AM, Gorio A, Bertelli A, Mantegazza P, Ferraris L, Ramacci MT (1992) Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int J Clin Pharmacol Res 12:243-246
15. Dyck PJ, Hansen S, Karnes J, O'Brien P, Yasuda H, Windebank A, Zimmerman B (1985) Capillary number and percentage closed in human diabetic neuropathy. Proc Natl Acad Sci USA 82: 2513-2517
16. Edelstein D, Brownlee M (1992) Mechanistic studies of advanced glycation end product inhibition by aminoguanidine. Diabetes 41:26-29
17. Gorio A, Di Giulio AM, Tenconi B, Donadoni L, Germani E, Bertelli A, Mantegazza P, Maccari F, Ramacci MT (1992) Peptide alterations in autonomic diabetic neuropathy prevented by acetyl-l-carnitine. Int J Clin Pharm Res 12: 225-230
18. Greene DA, Lewis RA, Lattimer SA, Brown MJ (1982) Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozotocin-diabetic rat. Diabetes 31:573-578
19. Greene DA, Lattimer SA, Sima AAF (1987) Sorbitol. phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Eng J Med 316:599-606
20. Ido Y, McHowat J, Chang KC, Arrigoni-Martelli E, Orfalian Z, Kilo C, Corr PB, Williamson JR (1994) Neural dysfunction and metabolic imbalances in diabetic rats: Prevention by acetyl-L-carnitine. Diabetes 43:1469-1477
21. Jain SK, McVie R, Duett J, Herbst JJ (1989) Erythrocyte membrane lipid peroxidation and glyeosylated haemoglobin in diabetes. Diabetes 38:1539-1543
22. Karasu C. Dewhurst M, Stevens EJ, Tomlinson DR (1995) Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozolocin-diabetic rats; comparison with essential fatty acids. Diabetologia 38:129-134
23. Kennnedy L, Baynes JW (1984) Nonenzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 26:93-98
24. Kumari K, Umar S, Bansal V, Sahib MK (1991a) Inhibition of diabetes associated complications by nucleophilic compounds. Diabetes 40:1079-1084
25. Kumari K, Umar S, Bansal V, Sahib MK (1991b) Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol 4:1527-1528
26. Lindell SE, Nilsson K, Roos B-E, Westling H (1960) The effect of enzymc inhibitors on histamine catabolism in man. Br J Pharmacol 15:351-355
27. Loven D, Schedl H, Wilson H, Daabes TT, Stegink LD, Diekus VI, Oberley L (1986) Effects of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozotocin-induced diabetes. Diabetes 35: 503-507
28. Low PA (1987) Recent advances in the pathogenesis of diabetic neuropathy Musele Nerve 10:121-128
29. Low PA, Nickander KK (1991) Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-877
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem. 193: 265-275
31. Malone JI, Lowitt S, Corsico N, Orfalian Z (1992) Altered neuroexeitability in experimental diabetic neuropathy: Effect of acetyl-L-carnitine. Int J Clin Pharm Res 12:237-241
32. McCord JM (1985) Oxygen-free radical effects in postischemic tissue injury. N Eng J Med 312:159-163
33. Merry AC, Kamijo M, Lattimer SA, Ristic H, Sima AAF (1994) Long term prevention and intervention effects of Acetyl-L-carnitine on diabetic neuropathy (Abstract). Diabetes 43 [Suppl 1]: 108A
34. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Titton RG, McDaniel ML, Williamson JR, Currie (1993) Selective inhibition of inducable nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233:119-125
35. Miyoshi T, Goto I (1973) Serial in vivo determinations of nerve conduction velocity in rat tails: physiological and pathological changes. Electroencephalogr Clin Neurophysiol 35: 125-131
36. Morabito E, Serafini S, Corsico N, Arrigoni Martelli (1993) Acetvl-L-carnitine effect on nerve conduction velocity in streptozotocin-diabetic rats. Arzneim- Forsch Drug Res 43:343-346
37. Nishigaki I, Hagihara M, Tsunekawa T, Masaki M, Yagi K (1981) Lipid peroxide level of serum lipoprotein fractions of diabetic patients. Biochem Med 25:373-378
38. Oberley LW (1988) Free radicals and diabetes. Free Radic Biol Med 5:113-124
39. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric-acid reaction. Anal Biochem 95:351-358
40. Picard S, Parthasarathy S, Fruebis J. Witztum JL (1992) Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89: 6870-6876
41. Pieper GM, Garrett JG (1988) Oxygen free radicals abolish endothelium dependent relaxation in diabetic rat aorta. Am J Physiol 255:H825-H833
42. Pitchard KA, Patel STJ, Karpen CW, Newman HAI, Pangamala RV (1986) Triglyceride lowering effect of dietary vitamin E in streptozotocin-induced diabetic rats. Increased lipoprotein lipase activity in livers of diabetic rats fed high dietary vitamin E. Diabetes 35:278-281
43. Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Guiglano D (1995) Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 38:123
44. Sass RL, Wermess P (1973) Acetylearnitine: on the relationship between structure and function. Biochem Biophys Res Commun 55:736-742
45. Saulis-Liparota T, Cooper ME, Dunlop M, Jerums G (1995) The relative roles of advanced glycation. oxidation and aldose reductase inhibition in the development of experimental diabetic neuropathy in the Spraque-Dawley rat. Diabetologia 38:387-394
46. Schmelzer JD, Zochodne DW, Low PA (1989) Ischemic and reperfusion injury of rat peripheral nerve. Proc Natl Acad Sci USA 86:1639-1642
47. Stevens MJ, Lattimer SA, Feldman E (1994) Protective effects of Acetyl-L-carnitine on ketogenesis and sciatic nerve function in the streptozocin diabetic rat (Abstract). Diabetes 43 [Suppl 1]:I7A
48. Stevens MJ, Lattimer SA, Greene DA (1995) Discrepant dose-responses of nerve conduction and Na/K-ATPase in the diabetic rat to acetyl-L-carnitine (Abstract). Diabelologia 38 [Suppl 1]:A7
49. Tesco G, Latoracca S, Piersanti P, Piacentini S, Amaducci L, Sorbi S (1992) Protection from oxygen radical damage in human diploid fibroblasts by acetyl- L-carnitine. Dementia 3:58-60
50. Winegrad Al (1987) Banting Lecture 1986. Does a common mechanism induce the diverse complications of diabetes? Diabetes 36:396-406
51. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K (1992) Effects of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52